Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of gene transfer therapies for serious disorders of the brain and CNS. Its technology is the only gene therapy strategy currently in development which bypasses the dopamine system that patients frequently develop complications from. Neurologix's investigational AAV (adeno-associated virus) vector gene therapy, NLX-P101, is a novel, non-dopaminergic approach that uses an inhibitory gene to selectively alter the neural circuitry affected in PD and, thereby, normalize brain physiology. The Phase 2 trial results demonstrated a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported. Patients enrolled in the trial had moderate to advanced PD and were not adequately responsive to current therapies.
"Based on this data, we are confident that NLX-P101 has great potential to advance the treatment paradigm for Parkinson's patients, and to eventually offer an important, new therapy for patients with this debilitating disease. The study investigators continue to further evaluate the detailed data and we look forward to its publication or presentation," said Clark A. Johnson, President and Chief Executive Officer of the Company. "Today's news is also important validation for our ongoing development of other technologies for neurological and psychiatric diseases, including our advanced pre-clinical program in epilepsy. Given these results, we would look to pursue a strategic transaction which will maximize value for the Company."
To view this article at World Market Media click on the link below: http://www.worldmarketmedia.com/779/section.aspx/1910/post/neurologix-inc-otcbb-nrgx-35m-marketcap-releases-successful-phase-2-trial-of-gene-therapy-for-parkinsons-disease
Disclosure: no positions